Immuno-Oncology | Specialty

Checkpoint Inhibitors Show Promise in Glioblastoma

November 19th 2016

Findings from the phase II trials KEYNOTE-028 of pembrolizumab and MEDI4736 (durvalumab) point to a role for checkpoint inhibitors in the treatment of glioblastoma multiforme, based on encouraging efficacy signals and safety data with the two agents.

Dr. Tripathy on Immunotherapy Potential in HER2-Positive Breast Cancer

November 19th 2016

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the potential role of immunotherapy in the treatment of patients with HER2-positive breast cancer.

Immunotherapy Becomes Mainstay in Bladder Cancer Care

November 19th 2016

The PD-1/PD-L1 inhibitors moving through the pipeline in bladder cancer will have a lasting impact on the armamentarium in the field, explains Jonathan E. Rosenberg, MD.

Vokes on Increasing Impact of Immunotherapy in Head and Neck Cancer

November 18th 2016

As immunotherapy continues to make headway in several different cancer types, these agents are only just arriving to the treatment landscape of head and neck cancer.

Expert Anticipates Avalanche of Data to Impact Treatment Landscape in NSCLC

November 18th 2016

Treatment in lung cancer continues to evolve at a rapid pace with the arrival of a set of efficacious new agents and promising evidence-based data. According to Corey J. Langer, MD, a veritable avalanche of additional data is on the way.

Dr. Iyer on Advice for Physicians Using Immunotherapy in Bladder Cancer

November 18th 2016

Gopa Iyer, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses significant points for community oncologists to be aware of when treating patients with bladder cancer with immunotherapy agents.

New Options Emerge in Frontline, Adjuvant RCC Care

November 17th 2016

Therapeutic options for patients with renal cell carcinoma have increased rapidly in the past decade, yet the field is still poised to expand significantly in the coming years, said Robert S. Alter, MD.

Pembrolizumab's Big Win in Immunotherapy Battle for Frontline in Lung Cancer

November 17th 2016

It has been about 18 months since the first immunotherapy checkpoint agent was approved for patients with non–small cell lung cancer. Now there are 3 monoclonal antibodies that target the PD-1/PD-L1 pathway on the market for the tumor type and the focus has shifted rapidly to establishng immunotherapy as a new frontline standard.

Sonja Althammer on Role of CD8 and PD-L1 Biomarkers for Immunotherapy in NSCLC

November 17th 2016

Sonja Althammer, PhD, Team Leader Bioinformatics at Definiens, Munich, Bavaria, Germany, discusses a study looking to define a subgroup of patients with non–small cell lung cancer (NSCLC) who respond well to treatment with the PD-L1 inhibitor durvalumab.

Dr. Suzanne L. Topalian on Immunotherapy Biomarkers in CRC

November 17th 2016

Suzanne L. Topalian, MD, professor of Surgery, Johns Hopkins Medicine, discuses novel immunotherapy biomarkers in colorectal cancer (CRC).

Biomarker Development Key to Optimizing Immunotherapy in Lung Cancer

November 17th 2016

The expression of PD-L1 has been at the forefront of biomarker development for PD-1/PD-L1 inhibitors, but there is much uncertainty surrounding its use and other biomarkers are needed.

Dr. Goldberg on PD-L1 as a Biomarker in Lung Cancer

November 17th 2016

Sarah B. Goldberg, MD, MPH, assistant professor of Medicine, Yale Cancer Center, discusses the use of PD-L1 as a biomarker in treating patients with lung cancer.

Improved Patient Selection Needed to Advance HER2+ Breast Cancer Care

November 17th 2016

Immunotherapy and chemotherapy are options physicians should not dismiss for patients with HER2-positive breast cancer, according to Lisa Carey, MD, even with the available targeted agents trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine.

Kantoff Highlights Continued Role for Docetaxel in Metastatic Prostate Cancer

November 16th 2016

While immunotherapy continues to make headway in various malignancies, the chemotherapy docetaxel maintains a key role in the treatment of patients with metastatic prostate cancer.

Dr. Borghaei on the Management of Immune-Related Side Effects in Lung Cancer

November 16th 2016

Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the management of slightly rarer side effects that patients with lung cancer can experience when treated with immunotherapy agents.

Lisa Butterfield on SITC Immune Biomarkers Task Force

November 16th 2016

Lisa Butterfield, PhD, professor of Medicine, Surgery and Immunology, director, University of Pittsburgh Cancer Institute Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, discusses the goals of the Society for Immunotherapy of Cancer (SITC) Immune Biomarkers Task Force during an interview at the SITC 31st Annual Meeting and Associated Programs.

Dual Biomarker Signature Holds Predictive Promise for Response to Anti-PD-L1 Therapy in NSCLC

November 16th 2016

Recent research suggests that the presence of PD-L1–positive and CD8+ cells may be useful for predicting responses in patients with non-small cell lung cancer who have been treated with durvalumab.

Pembrolizumab Antitumor Activity Promises Potential for Sarcoma Subtypes

November 15th 2016

Pembrolizumab reduced the size of tumors in patients with a subtype of soft tissue sarcoma, according to updated interim results from the phase II SARC028, multicenter clinical trial, which were reported at the most recent meeting of the Connective Tissue Oncology Society in Lisbon, Portugal.

Optimizing Frontline Immunotherapy in NSCLC

November 15th 2016

Immunotherapy continues to revolutionize the field of non–small cell lung cancer, with researchers now focusing on the optimal use of immune agents in the frontline setting.

Expert Discusses Next Steps With Immunotherapy in Lung Cancer

November 15th 2016

Hossein Borghaei, DO, discuss what lies ahead for immunotherapy in lung cancer, and what changes may be on the horizon for such agents as pembrolizumab (Keytruda), nivolumab (Opdivo), and ipilimumab (Yervoy) in the frontline setting.